Cancer Type: BrainHospitals offering this trial
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma (Study 2 Phase II).
This study is for subjects with a type of brain tumor called Glioblastoma Multiforme, which has progressed or recurred after initial treatment. No treatment has been shown to improve survival in such patients. Currently, bevacizumab is approved for such patients but has also not yet been shown to improve overall survival. Therefore, new treatment approaches are necessary for recurrent/progressive glioblastoma brain tumors. All subjects will receive bevacizumab as an IV infusion once every 2 weeks. In addition, subjects will be randomized (like the flip of a coin) to either take dasatinib tablets or a placebo (inactive tablets) twice a day every day.
Lombardi/MedStar Georgetown University Hospital
Contact: Jenny Crawford